Document:

EX-10.6

 Exhibit 10.6 
  

 
 VIA HAND DELIVERY 

March 19, 2017 
 Alejandra Carvajal 

 

	 	Re:	Retention Agreement 

 Dear Alejandra: 

As you know, Cerulean Pharma, Inc. (the “Company”) is exploring the possibility of a number of business opportunities and
transactions. We recognize and appreciate the contributions you have made to the Company during your employment and want you to remain committed to and focused on the tasks that you are assigned during this time. 

Accordingly, in lieu of providing you with any of the post-employment separation benefits set forth in the Employment Agreement between you
and the Company dated September 23, 2014 (as amended, the “Employment Agreement”), the Company has determined that you will be eligible to (i) receive a retention bonus payment equal to six (6) months of pay at your current
base salary rate (the “Retention Amount”), and (ii) receive an additional lump sum payment to assist you with the costs of obtaining health insurance in the amount of (x) the Company’s current monthly contribution to
Company-provided health and dental insurance coverage currently in effect with respect to your current coverage elections multiplied by (y) six (6) (the “Health Assistance Payment”), in each case payable at the time and on the
conditions set forth below and less all applicable taxes and withholdings, provided that: (a) your employment with the Company is not terminated by the Company for Cause (as defined below) or, for at least six (6) months following the date
of this letter agreement, by you for any reason without the Company’s agreement; (b) you execute and deliver to the Company no later than March 23, 2017 the Release of Claims Agreement attached hereto as Exhibit A (the “Release
Agreement”); and (c) you execute and deliver to the Company on, but not before, your last day of employment, the Reaffirmation of Release of Claims Agreement attached hereto as Exhibit B (the “Reaffirmation”). 

In addition, pursuant to the letter from the Company dated November 8, 2016 (the “November 2016 Letter”), you became eligible
for a retention bonus payment upon a Change in Control of the Company (as defined in Exhibit C) to the extent that you remained employed with the Company upon the closing of such Change in Control, on the terms and subject to the conditions in the
November 2016 Letter (the “CIC Bonus”). Notwithstanding that your last day of employment (the “Separation Date”) may be prior to any Change in Control of the Company, in the discretion of the Board of Directors, you may
nevertheless be eligible for a CIC Bonus of up to $78,573.29, payable on the terms and subject to the conditions determined by the Board. 

The Retention Amount will be paid to you within three (3) business days following your timely return of the Release Agreement, and the
Health Assistance Payment will be paid to you within three (3) business days following your timely return of the Reaffirmation. However, if you resign your 

  
 Cerulean Pharma Inc. | 35
Gatehouse Drive | Waltham, MA 02451 | P: 781-996-4300 | F: 844-894-CERU 

 

 
  

 
employment with the Company without the Company’s agreement for any reason prior to the date that is six (6) months following the date of this letter agreement, or should the Company
terminate your employment for Cause at any time, you will not be eligible to receive the Health Assistance Payment or the CIC Bonus, you will be required to repay the full amount of the Retention Amount to the Company immediately, and by signing
below and accepting the Retention Amount you agree to do so. For purposes of hereof, “Cause” means: (a) a good faith finding by the Company that you have (i) engaged in dishonesty, misconduct or gross negligence, or
(ii) violated a material Company policy or procedure or (b) your conviction of, or plea of guilty or nolo contendere to, any crime involving dishonesty or moral turpitude or any felony. 

Please note that your employment with the Company shall continue to be on an at-will basis, pursuant
to which both the Company and you remain free to end the employment relationship for any reason, at any time, with or without Cause or notice. To be clear, however, if the Company terminates your employment for any reason other than for Cause or if
you resign your employment with the Company’s agreement after you receive the Retention Amount, you will remain eligible to receive the Health Assistance Payment and CIC Bonus (to the extent payable), and you will not be required to repay any
portion of the Retention Amount to the Company. 
 Nothing in this letter agreement shall be construed as an agreement, either express or
implied, to pay you any compensation or grant you any benefit beyond the end of your employment with the Company, except as explicitly set forth herein. You may, however, if eligible, elect to continue receiving group health insurance at your own
expense pursuant to the law known as “COBRA.” Please consult the COBRA materials to be provided under separate cover for details regarding this benefit. Please also note that if, following the end of your employment, the Company ceases to
maintain a group health plan, your COBRA coverage will cease. You may, however, be able to obtain health coverage through the Massachusetts health exchange, to the extent you are eligible and as permitted by applicable law. 

This letter agreement shall be interpreted and construed by the laws of the Commonwealth of Massachusetts, without regard to conflict of laws
provisions. You hereby irrevocably submit to and acknowledge and recognize the jurisdiction of the courts of the Commonwealth of Massachusetts or if appropriate, a federal court located in the Commonwealth of Massachusetts (which courts, for
purposes of this letter agreement, are the only courts of competent jurisdiction), over any suit, action or other proceeding arising out of, under or in connection with this letter agreement or the subject matter hereof. This letter agreement is
intended to comply with or be exempt from the provisions of Section 409A and the letter agreement will, to the extent practicable, be construed in accordance therewith. The Company makes no representations or warranty and will have no liability to
you or any other person if any provisions of or payments under this letter agreement are determined to constitute deferred compensation subject to Code Section 409A but not to satisfy the conditions of that section. 

Please note that this letter agreement supersedes in their entirety the provisions of the Employment Agreement providing for post-employment
separation benefits, and that by signing this letter agreement and Exhibit A you will be waiving any rights or claims to receive any such benefits pursuant to, or otherwise arising out of or relating to, the Employment Agreement. 

  
 Cerulean Pharma Inc. | 35
Gatehouse Drive | Waltham, MA 02451 | P: 781-996-4300 | F: 844-894-CERU 

 

 
  

 Please review carefully this letter agreement and Exhibits A, B and C and let me know if you
have any questions. If you wish to be eligible to receive, in lieu of and in exchange for relinquishing the post-employment separation benefits set forth in the Employment Agreement, the Retention Amount, Health Assistance Payment and CIC Bonus (to
the extent payable) described herein pursuant to the terms and conditions hereof, please sign this letter agreement and Exhibit A and return them to me no later than March 23, 2017, and please sign and return Exhibit B on, but not before, the
Separation Date. 
  

			
	Sincerely,
		
	By:	 	 /s/ Christopher D. T. Guiffre

		 	Christopher D. T. Guiffre
		 	President & Chief Executive Officer

  

					
	Received, acknowledged and agreed:	 		 	
			
	 /s/ Alejandra Carvajal
	 		 	 March 19, 2017

	Alejandra Carvajal	 		 	Date

  
 Cerulean Pharma Inc. | 35
Gatehouse Drive | Waltham, MA 02451 | P: 781-996-4300 | F: 844-894-CERU 

 

 
  

 EXHIBIT A 

RELEASE OF CLAIMS AGREEMENT 
 In
exchange for the consideration set forth in the letter agreement dated March 19, 2017 (the “Letter Agreement”) to which this Release of Claims Agreement (the “Release Agreement”) is attached as Exhibit A, including receipt
of the Retention Amount (as defined therein) and eligibility to receive the Health Assistance Payment and CIC Bonus (to the extent payable) (each as defined therein), all of which I acknowledge I would not otherwise be entitled to receive, I hereby
agree as follows: 
 1. Release – I hereby fully, forever, irrevocably and unconditionally release, remise and discharge
the Company, its affiliates, subsidiaries, parent companies, predecessors, and successors, and all of their respective past and present officers, directors, stockholders, partners, members, managers, employees, agents, representatives, plan
administrators, attorneys, insurers and fiduciaries (each in their individual and corporate capacities) (collectively, the “Released Parties”) from any and all claims, charges, complaints, demands, actions, causes of action, suits, rights,
debts, sums of money, costs, accounts, reckonings, covenants, contracts, agreements, promises, doings, omissions, damages, executions, obligations, liabilities, and expenses (including attorneys’ fees and costs), of every kind and nature that I
ever had or now have against any or all of the Released Parties, including, but not limited to, any and all claims arising out of or relating to my employment with and/or separation from the Company, including, but not limited to, the following and
any and all claims for or related to aiding or abetting the following, whether direct or derivative, and whether brought myself or by or through the Company or any trustee, assignee, agent, or other representative thereof: all claims under Title VII
of the Civil Rights Act of 1964, 42 U.S.C. § 2000e et seq., the Americans With Disabilities Act of 1990, 42 U.S.C. § 12101 et seq., the Genetic Information Nondiscrimination Act of 2008, 42 U.S.C. §
2000ff et seq., the Family and Medical Leave Act, 29 U.S.C. § 2601 et seq., the Worker Adjustment and Retraining Notification Act (“WARN”), 29 U.S.C. § 2101 et seq., the Rehabilitation
Act of 1973, 29 U.S.C. § 701 et seq., Executive Order 11246, Executive Order 11141, the Fair Credit Reporting Act, 15 U.S.C. § 1681 et seq., and the Employee Retirement Income Security Act of 1974
(“ERISA”), 29 U.S.C. § 1001 et seq., all as amended; all claims arising out of the Massachusetts Fair Employment Practices Act, Mass. Gen. Laws ch. 151B, § 1 et seq., the Massachusetts Wage Act, Mass.
Gen. Laws ch. 149, § 148 et seq. (Massachusetts law regarding payment of wages and overtime), the Massachusetts Civil Rights Act, Mass. Gen. Laws ch. 12, §§ 11H and 11I, the Massachusetts Equal Rights Act, Mass. Gen.
Laws. ch. 93, § 102 and Mass. Gen. Laws ch. 214, § 1C, the Massachusetts Labor and Industries Act, Mass. Gen. Laws ch. 149, § 1 et seq., Mass. Gen. Laws ch. 214, § 1B (Massachusetts right of privacy law),
the Massachusetts Maternity Leave Act, Mass. Gen. Laws ch. 149, § 105D, and the Massachusetts Small Necessities Leave Act, Mass. Gen. Laws ch. 149, § 52D, all as amended; all common law claims including, but not limited to, actions in
defamation, intentional infliction of emotional distress, breach of duty, misrepresentation, fraud, fraudulent transfer, wrongful discharge, and breach of contract (including, without limitation, any claims arising out of or related to the
Employment Agreement (as defined in the Letter Agreement)); all claims to any ownership interest in the Company, contractual or otherwise; all state and federal whistleblower claims to the maximum extent permitted by law; and any claim or damage
arising out of my employment with and/or separation from the Company (including a claim for retaliation) under any common law theory or any federal, state or local statute or ordinance not expressly referenced above; provided, however, that nothing
in this Release Agreement (a) prevents me 

  
 Cerulean Pharma Inc. | 35
Gatehouse Drive | Waltham, MA 02451 | P: 781-996-4300 | F: 844-894-CERU 

 

 
  

 
from filing a charge with, cooperating with, or participating in any investigation or proceeding before, the Equal Employment Opportunity Commission or a state fair employment practices agency
(except that I acknowledge that I may not recover any monetary benefits in connection with any such charge, investigation, or proceeding, and I further waive any rights or claims to any payment, benefit, attorneys’ fees or other remedial relief
in connection with any such charge, investigation or proceeding). 
 2. Continuing Obligations – I
acknowledge and reaffirm my obligation to keep confidential and not to use or disclose any and all non-public information concerning the Company that I acquired during the course of my employment with the
Company, including any non-public information concerning the Company’s business affairs, business prospects, and financial condition, except as otherwise permitted by paragraph 7 below. Further, I
acknowledge that I remain subject to any and all continuing confidentiality and other obligations that I have pursuant to any previous agreement with the Company, including, but not limited to, the
Non-Disclosure, Non-Competition and Assignment of Intellectual Property Agreement which I executed in connection with my employment, and which remains in full force and
effect. 
 3. Non-Disparagement – I understand and agree that, to the extent permitted by law and except as otherwise
permitted by paragraph 7 below, I will not, in public or private, make any false, disparaging, derogatory or defamatory statements, online (including, without limitation, on any social media, networking, or employer review site) or otherwise, to any
person or entity, including, but not limited to, any media outlet, industry group, financial institution or current or former employee, board member, consultant, client or customer of the Company, regarding the Company or any of the other Released
Parties, or regarding the Company’s business affairs, business prospects, or financial condition. 
 4. Cooperation
– I agree that, to the extent permitted by law, I shall cooperate fully with the Company in the investigation, defense or prosecution of any claims or actions which already have been brought, are currently pending, or which may be brought in
the future against the Company by a third party or by or on behalf of the Company against any third party, whether before a state or federal court, any state or federal government agency, or a mediator or arbitrator. My full cooperation in
connection with such claims or actions shall include, but not be limited to, being available to meet with the Company’s counsel, at reasonable times and locations designated by the Company, to investigate or prepare the Company’s claims or
defenses, to prepare for trial or discovery or an administrative hearing, mediation, arbitration or other proceeding and to act as a witness when requested by the Company. I further agree that, to the extent permitted by law, I will notify the
Company promptly in the event that I am served with a subpoena (other than a subpoena issued by a government agency), or in the event that I am asked to provide a third party (other than a government agency) with information concerning any actual or
potential complaint or claim against the Company. 
 5. Return of Company
Property and Information – I agree that on the Separation Date (as defined in the Letter Agreement), or earlier upon request by the Company, I will return to the Company all keys,
files, records (and copies thereof), equipment (including, but not limited to, computer hardware, software and printers, flash drives and storage devices, wireless handheld devices, cellular phones, tablets, etc.), Company identification, and any
other Company-owned property and information in my possession or control and that I will leave intact all electronic Company documents and 

  
 Cerulean Pharma Inc. | 35
Gatehouse Drive | Waltham, MA 02451 | P: 781-996-4300 | F: 844-894-CERU 

 

 
  

 
information, including but not limited to those documents and that information that I developed or helped to develop during my employment, and I will not retain any copies. I further confirm that
I will, on the Separation Date, or earlier upon request by the Company, cancel all accounts for my benefit, if any, in the Company’s name, including but not limited to, credit cards, telephone charge cards, cellular phone accounts, and computer
accounts. 
 6. Confidentiality – I understand and agree that, to the extent permitted by law and except as otherwise
permitted by paragraph 7 below, the terms and contents of this Release Agreement and the Letter Agreement, and the contents of the negotiations and discussions resulting in this Release Agreement and the Letter Agreement, shall be maintained as
confidential by me and my agents and representatives and shall not be disclosed except as otherwise agreed to in writing by the Company. 

7. Scope of Disclosure Restrictions – I understand that
nothing in this Release Agreement or elsewhere prohibits me from communicating with government agencies about possible violations of federal, state, or local laws or otherwise providing information to government agencies, filing a complaint with
government agencies, or participating in government agency investigations or proceedings. I understand that I am not required to notify the Company of any such communications; provided, however, that nothing herein authorizes the disclosure of
information I obtained through a communication that was subject to the attorney-client privilege. Further, notwithstanding my confidentiality and nondisclosure obligations, I understand that I am hereby being advised as follows pursuant to the
Defend Trade Secrets Act: “An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local
government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other
proceeding, if such filing is made under seal. An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret
information in the court proceeding, if the individual (A) files any document containing the trade secret under seal; and (B) does not disclose the trade secret, except pursuant to court order.” 

8. Amendment and Waiver; Successors and
Assigns – This Release Agreement may not be modified in any manner, except by an instrument in writing of concurrent or subsequent date signed by duly authorized representatives of the Company. This Release Agreement is
binding upon me and my agents, assigns, heirs, executors, successors and administrators, and any party acting on my behalf or by or through myself or my rights, and shall inure to the benefit of the Company’s agents, assigns, successors and
administrators. No delay or omission by the Company in exercising any right under this Release Agreement shall operate as a waiver of that or any other right. A waiver or consent given by the Company on any one occasion shall be effective only in
that instance and shall not be construed as a bar to or waiver of any right on any other occasion. 
 9. Validity –
Should any provision of this Release Agreement be declared or be determined by any court of competent jurisdiction to be illegal or invalid, the validity of the remaining parts, terms or provisions shall not be affected thereby and said illegal or
invalid part, term or provision shall be deemed not to be a part of this Release Agreement. 

  
 Cerulean Pharma Inc. | 35
Gatehouse Drive | Waltham, MA 02451 | P: 781-996-4300 | F: 844-894-CERU 

 

 
  

 10. Nature of Agreement –
I understand and agree that this Release Agreement does not constitute an admission of liability or wrongdoing on the part of the Company. 

11. Acknowledgments and Voluntary Assent – I
acknowledge that I have been given a reasonable amount of time to consider this Release Agreement. I affirm that no other promises or agreements of any kind have been made to or with me by any person or entity whatsoever to cause me to sign this
Release Agreement, and that I fully understand the meaning and intent of this Release Agreement. I state and represent that I have had an opportunity to fully discuss and review the terms of this Release Agreement with an attorney. I further state
and represent that I have carefully read this Release Agreement, understand the contents herein, freely and voluntarily assent to all of the terms and conditions hereof, and sign my name of my own free act. 

12. Applicable Law – This Release Agreement shall be interpreted and construed by the laws of the
Commonwealth of Massachusetts, without regard to conflict of laws provisions. I hereby irrevocably submit to and acknowledge and recognize the jurisdiction of the courts of the Commonwealth of Massachusetts, or if appropriate, a federal court
located in the Commonwealth of Massachusetts (which courts, for purposes of this Release Agreement, are the only courts of competent jurisdiction), over any suit, action or other proceeding arising out of, under or in connection with this Release
Agreement or the subject matter hereof. 
 13. Entire Agreement – This Release Agreement, together
with the Letter Agreement, contains and constitutes the entire understanding and agreement between the parties hereto with respect to the subject matter thereof and cancels any and all previous oral and written negotiations, agreements, and
commitments in connection therewith. 
 14. Tax Acknowledgement – In connection with the Retention
Amount, Health Assistance Payment and CIC Bonus (to the extent payable) described in the Letter Agreement, I understand that the Company shall withhold and remit to the tax authorities the amounts required under applicable law, and that I shall be
responsible for all applicable taxes with respect to such payments and benefits under applicable law. I further acknowledge that I am not relying upon the advice or representation of the Company with respect to the tax treatment of any payments or
benefits described in the Letter Agreement. 
 I hereby agree to the terms and conditions set forth above. 

 

					
	 /s/ Alejandra Carvajal
	 		 	 March 19, 2017

	Alejandra Carvajal	 		 	Date

 To be returned in a timely manner as set forth in the Letter Agreement. 

  
 Cerulean Pharma Inc. | 35
Gatehouse Drive | Waltham, MA 02451 | P: 781-996-4300 | F: 844-894-CERU 

 

 
  

 EXHIBIT B 

REAFFIRMATION OF RELEASE OF CLAIMS AGREEMENT 

I hereby reaffirm as of the date below my agreement to all of the terms and conditions set in the forth in the Release of Claims Agreement attached as Exhibit
A to the letter agreement dated March 19, 2017 (the “Letter Agreement”) to which this Exhibit B is attached. I further agree that I have received payment for all wages due, all accrued but unused paid time off and any other amounts
due and owing through the Separation Date (as defined in the Letter Agreement). I further confirm that I have complied with all of the provisions of paragraph 5 of Exhibit A. 
  

					
	  
	 		 	  

	Alejandra Carvajal	 		 	Date

  
 Cerulean Pharma Inc. | 35
Gatehouse Drive | Waltham, MA 02451 | P: 781-996-4300 | F: 844-894-CERU 

 

 
  

 EXHIBIT C 

Definition of Change in Control 

1. “Change in Control” means an event or occurrence set forth in any one or more of subsections (i) through (iii) below (including an
event or occurrence that constitutes a Change in Control under one of such subsections but is specifically exempted from another such subsection), provided that such event constitutes a “change in control event” within the meaning of
Treasury Regulation Section 1.409A-3(i)(5)(i): 
 (i) the acquisition by an individual, entity
or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) (a “Person”) of beneficial ownership of any capital stock of the Company if, after such
acquisition, such Person beneficially owns (within the meaning of Rule 13d-3 promulgated under the Exchange Act) more than 50% of either (x) the then-outstanding shares of common stock of the Company (the
“Outstanding Company Common Stock”) or (y) the combined voting power of the then-outstanding securities of the Company entitled to vote generally in the election of directors (the “Outstanding Company Voting Securities”); or

 (ii) the consummation of a merger, consolidation, reorganization, recapitalization or share exchange involving the Company or a sale or
other disposition of all or substantially all of the assets of the Company in one or a series of transactions (a “Business Combination”), unless, immediately following such Business Combination, all or substantially all of the individuals
and entities who were the beneficial owners of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50% of the
then-outstanding shares of common stock and the combined voting power of the then-outstanding securities entitled to vote generally in the election of directors, respectively, of the resulting or acquiring corporation in such Business Combination
(which shall include, without limitation, a corporation which as a result of such transaction owns the Company or substantially all of the Company’s assets either directly or through one or more subsidiaries) (such resulting or acquiring
corporation is referred to herein as the “Acquiring Corporation”) in substantially the same proportions as their ownership, immediately prior to such Business Combination, of the Outstanding Company Common Stock and Outstanding Company
Voting Securities, respectively; or 
 (iii) approval by the stockholders of the Company of a complete or substantially complete liquidation
or dissolution of the Company. 

  
 Cerulean Pharma Inc. | 35
Gatehouse Drive | Waltham, MA 02451 | P: 781-996-4300 | F: 844-894-CERUExhibit 10.1

 

 

SECOND AMENDMENT

TO CREDIT AGREEMENT

 

This Second Amendment
to Credit Agreement, dated as of March 17, 2017 (this “Amendment”), by and among each of the lenders party hereto,
Greatbatch Ltd., a New York corporation (the “Borrower”), Integer Holdings Corporation (f/k/a Greatbatch, Inc.),
a Delaware corporation (“Parent”), Manufacturers and Traders Trust Company, as the administrative agent under
the Credit Agreement referred to below (in such capacity, the “Administrative Agent”) and Credit Suisse Securities
(USA) LLC (in such capacity, the “Arranger”). Capitalized terms used herein without definition shall have the
same meanings herein as set forth in the Credit Agreement after giving effect to this Amendment.

 

WHEREAS, reference is
hereby made to that certain Credit Agreement, dated as of October 27, 2015 (as modified pursuant to that certain Consent of Lenders,
dated as of February 9, 2016 and that certain Memorandum of Correction, dated as of April 19, 2016, as amended by that certain
Amendment No. 1 to Credit Agreement, dated as of November 29, 2016, and as further amended, restated, supplemented or otherwise
modified and as in effect immediately prior to the Amendment Effective Date (as defined below), the “Credit Agreement”),
among, inter alios, the Borrower, Parent, the Administrative Agent and each Lender from time to time party thereto (capitalized
terms used but not defined herein having the meaning provided in the Credit Agreement);

 

WHEREAS, the Borrower
and Parent have requested that certain amendments and modifications to the Credit Agreement be effected, including to permit the
refinancing of all outstanding Term B Loans as contemplated by Section 2.19.1 of the Credit Agreement as described herein;

 

WHEREAS, subject to certain
conditions, such amendments and modifications shall include the addition of a new term loan facility (the “New Term B
Facility”; the loans thereunder, the “New Term B Loans”) the proceeds of which New Term B Loans shall
be used to replace the outstanding Term B Loans;

 

WHEREAS, the New Term
B Loans will have the same terms as the Term B Loans currently outstanding under the Credit Agreement except as otherwise set forth
herein;

 

WHEREAS, each existing
Term B Lender (each, an “Existing Term B Lender” and the existing Term B Loans held by it, its “Existing
Term B Loans”) that executes and delivers a signature page to the ‘Lender New Commitment’ dated March 17,
2017 (the “Lender New Commitment”), and in connection therewith agrees to continue all or a portion (as determined
by the Arranger and notified to such Lender) of its outstanding Existing Term B Loans as New Term B Loans (such continued Term
B Loans, the “Continued Term B Loans” and such Term B Lenders, collectively, the “Continuing Term B
Lenders”) will thereby (i) agree to the terms of this Amendment and (ii) agree to continue all or such portion (as determined
by the Administrative Agent and notified to such Lender) of its Existing Term B Loans outstanding on the Amendment Effective Date
as New Term B Loans in a principal amount equal to the aggregate outstanding principal amount of such Existing Term B Loans so
continued;

 

WHEREAS, each Person
(other than a Continuing Term B Lender in its capacity as such and in the amount of its Continued Term B Loans) that agrees to
make New Term B Loans (collectively, the “Additional Term B Lenders”) will make New Term B Loans to the Borrower
on the Amendment Effective Date in such amount (not in excess of its commitment) as determined by the Administrative Agent and
notified to such Additional Term B Lender;

 

WHEREAS, the Continuing
Term B Lenders and the Additional Term B Lenders (collectively, the “New Term B Lenders”) are severally willing
to continue all or a portion (as determined by the Administrative Agent and notified to such Lender) of their Existing Term B Loans
as New Term B Loans and/or to make New Term B Loans, as the case may be, subject to the terms and conditions set forth in this
Amendment;

 

    

     

    

WHEREAS, notwithstanding
the foregoing, any Existing Term B Lender that does not become a Continuing Term B Lender as contemplated hereby shall not otherwise
be permitted to become an Additional Term B Lender or a Continuing Term B Lender, unless approved by the Administrative Agent;
and

 

WHEREAS, the New Term
B Lenders and the Administrative Agent are willing to agree to this Amendment on the terms set forth herein.

 

NOW, THEREFORE, in consideration
of the premises and the agreements, provisions and covenants herein contained and other good and valuable consideration, the sufficiency
and receipt of which are hereby acknowledged, the parties hereto agree as follows:

 

		SECTION I.
     	NEW TERM LOANS

 

A.                
Subject to the terms and conditions set forth herein, (i) each Continuing Term B Lender agrees to continue all or a
portion (as determined by the Administrative Agent and notified to such Lender) of its Existing Term B Loans as a New Term B Loan
on the date requested by the Borrower to be the Amendment Effective Date in a principal amount equal to such Existing Term B Loans
and (ii) each Additional Term B Lender agrees to make New Term B Loans on such date to the Borrower in a principal amount equal
to such Additional Term B Lender’s New Term B Loan Commitment (as defined below).  For purposes hereof, a Person may
become a party to the Credit Agreement as amended hereby and become a New Term B Lender as of the Amendment Effective Date by executing
this Amendment or the Lender New Commitment, as applicable, and delivering to the Administrative Agent, on or prior to the Amendment
Effective Date, a counterpart signature page to this Amendment or the Lender New Commitment, as applicable, in its capacity as
a New Term B Lender.  The Borrower shall give notice to the Administrative Agent of the proposed Amendment Effective Date
not later than one Business Day prior thereto, and the Administrative Agent shall notify each New Term B Lender thereof. 
For the avoidance of doubt, the Existing Term B Loans of a Continuing Term B Lender must be continued in whole and may not be continued
in part unless approved or otherwise determined by the Administrative Agent.

 

B.                
Each Additional Term B Lender will make its New Term B Loan on the Amendment Effective Date by making available to the
Administrative Agent, in accordance with the Credit Agreement, an amount equal to its New Term B Loan Commitment.  The “New
Term B Loan Commitment” of any Additional Term B Lender will be such amount (not exceeding any commitment offered by
such Additional Term B Lender) allocated to it by the Administrative Agent and notified to it on or prior to the Amendment Effective
Date.  The commitments of the Additional Term B Lenders and the continuation undertakings of the Continuing Term B Lenders
are several and no such Lender will be responsible for any other such Lender’s failure to make or acquire by continuation
its New Term B Loan.  The New Term B Loans may from time to time be Base Rate Loans or LIBOR Loans, as determined by the Borrower
and notified to the Administrative Agent in accordance with the Credit Agreement. Each New Term B Lender, as to itself, hereby
agrees to waive any indemnity claim for breakage costs under Section 2.8.5 of the Credit Agreement in connection with the prepayment
or replacement of Existing Term B Loans contemplated hereby.

 

    

     

    

C.                
The obligation of each New Term B Lender to make or acquire by continuation New Term B Loans on the Amendment Effective
Date is subject to the satisfaction of the conditions set forth in Section III of this Amendment.

 

D.                
On and after the Amendment Effective Date, each reference in the Loan Documents to “Term B Loans” shall
be deemed a reference to the New Term B Loans contemplated hereby, except as the context may otherwise require, each reference
to “Term B Lenders” shall be deemed a reference to the New Term B Lenders.  Notwithstanding the foregoing, the
provisions of the Credit Agreement with respect to indemnification, reimbursement of costs and expenses, increased costs and break
funding payments shall continue in full force and effect with respect to, and for the benefit of, each Existing Term B Lender in
respect of such Lender’s Existing Term B Loans.

 

E.                
The principal of the New Term B Loans shall be due and payable in quarterly installments, each equal to (a) one-quarter
of two and a half percent (0.625%) for each payment due on March 31, 2017, June 30, 2017, September 30, 2017 and December 31, 2017
and (b) one-quarter of one percent (0.250%) on each Quarterly Payment Date that occurs after December 31, 2017 and continuing through
(and including) the last Quarterly Payment Date prior to the Term B Loan Maturity Date, in each case, calculated as a percentage
of the original principal amount subject to adjustment pursuant to the terms of the Credit Agreement as amended by this Amendment);
provided that each New Term B Lender hereby acknowledges and agrees that the Borrower has prepaid, prior to the date hereof, all
amounts due pursuant to this paragraph other than the payment of (x) one-quarter of two and a half percent (0.625%) of the original
principal amount on March 31, 2017 and (y) one quarter of one and a half percent (0.375%) of the original principal amount on June
30, 2017, September 30, 2017 and December 31, 2017. All amounts of principal, interest and fees relating to Refinancing Loans not
due and payable before the Term B Loan Maturity Date are due and payable on the Term B Loan Maturity Date.

 

F.                 
The final maturity date of the New Term B Loans shall be the Term B Loan Maturity Date.

 

G.               
The continuation of Continued Term B Loans may be implemented pursuant to other procedures specified by the Administrative
Agent (in consultation with the Borrower), including by repayment of Continued Term B Loans of a Continuing Term B Lender from
the proceeds of New Term B Loans followed by a subsequent assignment to it of New Term B Loans in the same amount and each Continuing
Term B Lender hereby agrees to execute such other documentation as may be required to evidence such Continuing Term B Lender’s
New Term B Loan Commitment.

 

		SECTION II.     	AMENDMENTS
TO CREDIT AGREEMENT

 

		2.1	Amendments to Section 1: Definitions.

 

A.                
Section 1.1 of the Credit Agreement is hereby amended by adding the following definitions in proper alphabetical
sequence:

 

“Additional
Term B Lender” shall have the meaning set forth in the Second Amendment.

 

“Bail-In Action” shall
mean the exercise of any Write-Down and Conversion Powers by the applicable EEA Resolution Authority in respect of any liability
of an EEA Financial Institution.

 

“Bail-In Legislation”
shall mean, with respect to any EEA Member Country implementing Article 55 of Directive 2014/59/EU of the European Parliament and
of the Council of the European Union, the implementing law for such EEA Member Country from time to time which is described in
the EU Bail-In Legislation Schedule.

 

    

     

    

“Continuing
Term B Lenders” shall have the meaning set forth in the Second Amendment.

 

“EEA Financial Institution”
shall mean (a) any credit institution or investment firm established in any EEA Member Country which is subject to the supervision
of an EEA Resolution Authority, (b) any entity established in an EEA Member Country which is a parent of an institution described
in clause (a) of this definition, or (c) any financial institution established in an EEA Member Country which is a subsidiary of
an institution described in clauses (a) or (b) of this definition and is subject to consolidated supervision with its parent.

 

“EEA Member Country”
shall mean any of the member states of the European Union, Iceland, Liechtenstein, and Norway.

 

“EEA Resolution Authority”
shall mean any public administrative authority or any person entrusted with public administrative authority of any EEA Member Country
(including any delegee) having responsibility for the resolution of any EEA Financial Institution.

 

“EU Bail-In
Legislation Schedule” shall mean the EU Bail-In Legislation Schedule published by the Loan Market Association (or any
successor person), as in effect from time to time.

 

“Second
Amendment” shall mean that certain Second Amendment to Credit Agreement dated as of March 17, 2017 among the Borrower,
Parent, the other Loan Parties party thereto, the Administrative Agent, and the Lenders party thereto.

 

“Second
Amendment Effective Date” shall mean March 17, 2017, the date on which the conditions precedent set forth in Section
III of the Second Amendment were satisfied or waived in accordance therewith.

 

“Write-Down
and Conversion Powers” shall mean, with respect to any EEA Resolution Authority, the write-down and conversion powers
of such EEA Resolution Authority from time to time under the Bail-In Legislation for the applicable EEA Member Country, which write-down
and conversion powers are described in the EU Bail-In Legislation Schedule.

 

B.                
The definition of “Term B Lender” in Section 1.1 of the Credit Agreement is hereby amended and restated
in its entirety as follows:

 

““Term B Lender”:
each Lender that signs the Second Amendment in respect of a Term B Loan Commitment. Each Additional Term B Lender shall be a Term
B Lender to the extent any such Person has executed the Second Amendment and to the extent such Second Amendment shall have become
effective in accordance with the terms hereof and thereof, and each Continuing Term B Lender shall continue to be a Term B Lender.
The Term B Lenders as of the Second Amendment Effective Date shall be as set forth in the Register at the time the Register is
updated and/or modified to reflect and give effect to the Second Amendment and the transactions contemplated thereby.”

 

    

     

    

C.                
The definition of “Defaulting Lender” in Section 1.1 of the Credit Agreement is hereby amended and restated
in its entirety as follows”

 

“Defaulting Lender”:
subject to Subsection 2.15.2 (Defaulting Lender Cure), any Lender that (a) has failed to (i) fund all or any portion of its Loans
within two (2) Business Days of the date such Loans were required to be funded hereunder unless such Lender notifies the Administrative
Agent and the Borrower in writing that such failure is the result of such Lender’s determination that one or more conditions
precedent to funding (each of which conditions precedent, together with any applicable default, shall be specifically identified
in such writing) has not been satisfied, or (ii) pay to the Administrative Agent, any Issuing Bank, any Swingline Lender or any
other Lender any other amount required to be paid by it hereunder (including in respect of its participation in Letters of Credit
or Swingline Loans) within two (2) Business Days of the date when due, (b) has notified the Borrower, the Administrative Agent
or any Issuing Bank or Swingline Lender in writing that it does not intend to comply with its funding obligations hereunder, or
has made a public statement to that effect (unless such writing or public statement relates to such Lender’s obligation to
fund a Loan hereunder and states that such position is based on such Lender’s determination that a condition precedent to
funding (which condition precedent, together with any applicable default, shall be specifically identified in such writing or public
statement) cannot be satisfied), (c) has failed, within three (3) Business Days after written request by the Administrative Agent
or the Borrower, to confirm in writing to the Administrative Agent and the Borrower that it will comply with its prospective funding
obligations hereunder (provided, that such Lender shall cease to be a Defaulting Lender pursuant to this clause (c) upon receipt
of such written confirmation by the Administrative Agent and the Borrower) or (d) unless the Administrative Agent determines in
its sole discretion that a Lender should not be a Defaulting Lender by virtue of the facts and circumstances described in this
clause (d) has, or has a direct or indirect parent company that has, (i) become the subject of a proceeding under any Debtor Relief
Law, (ii) become the subject of a Bail-in Action, or (iii) had appointed for it a receiver, custodian, conservator, trustee, administrator,
assignee for the benefit of creditors or similar Person charged with reorganization or liquidation of its business or assets, including
the Federal Deposit Insurance Corporation or any other state or federal regulatory authority acting in such a capacity; provided,
that a Lender shall not be a Defaulting Lender solely by virtue of the ownership or acquisition of any equity interest in that
Lender or any direct or indirect parent company thereof by a Governmental Authority so long as such ownership interest does not
result in or provide such Lender with immunity from the jurisdiction of courts within the United States or from the enforcement
of judgments or writs of attachment on its assets or permit such Lender (or such Governmental Authority) to reject, repudiate,
disavow or disaffirm any contracts or agreements made with such Lender. Any determination by the Administrative Agent that a Lender
is a Defaulting Lender under any one or more of clauses (a) through (d) above shall be conclusive and binding absent manifest error,
and such Lender shall be deemed to be a Defaulting Lender (subject to Subsection 2.15.2 (Defaulting Lender Cure)) upon delivery
of written notice of such determination to the Borrower, each Issuing Bank, each Swingline Lender and each Lender.

 

		2.2	The definition “Repricing Event” in Section 1.1 of
the Credit Agreement is hereby amended by substituting the references to “Initial Term B Loans” to “Term B Loans”

 

		2.3	Amendments to Section 2.1.4: Commitment to make Term B Loans.

 

Section 2.1.4 is hereby amended
and restated in its entirety as follows:

 

“Upon the terms and subject
to the conditions of the this Agreement, each Term B Lender agrees to make advances, including, as applicable, its obligation under
the Second Amendment to continue its outstanding “Existing Term B Loans” as “Continued Term B Loans” as
such terms are defined in the Second Amendment (such advances, together with any Incremental Term B Loans, the “Term
B Loans”) to the Borrower on the Second Amendment Effective Date in an aggregate outstanding principal amount not
to exceed Nine Hundred Fifty Four Million Two Hundred Fifty Thousand Dollars ($954,250,000) (as the same may be increased or reduced,
pursuant to the terms of this Agreement, the “Term B Loan Commitment”); provided, however, that the amount and
percentage of the Term B Loan Commitment that any Lender is obligated to lend shall not exceed the amount or percentage set forth
on Schedule 2.1.4 for such Term B Lender (as supplemented and amended by giving effect to the assignments contemplated by this
Agreement and any other adjustments contemplated by this Agreement). The Term B Loan Commitment of any Term B Lender is sometimes
referred to herein as such Term B Lender’s Term B Loan Commitment. The Borrower shall not be permitted to reborrow any amount
of the Term B Loans once repaid”.

 

    

     

    

		2.4	Amendments to Section 2.1.7: Scheduled Repayment of Term B Loans.

 

Section 2.1.7 is hereby amended
and restated in its entirety as follows”

 

“The principal of the Term
B Loans shall be due and payable in quarterly installments, each equal to (a) one-quarter of two and a half percent (0.625%) for
each payment due on March 31, 2017, June 30, 2017, September 30, 2017 and December 31, 2017 and (b) one-quarter of one percent
(0.250%) on each Quarterly Payment Date that occurs after December 31, 2017 and continuing through (and including) the last Quarterly
Payment Date prior to the Term B Loan Maturity Date thereafter, in each case, calculated as a percentage of the original principal
amount subject to adjustment pursuant to the terms of this Agreement); provided that each Term B Lender hereby acknowledges and
agrees that the Borrower has prepaid, prior to the Second Amendment Effective Date, all amounts due pursuant to this paragraph
other than the payment of (x) one-quarter of two and a half percent (0.625%) of the original principal amount on March 31, 2017
and (y) one-quarter of one and a half percent (0.375%) of the original principal amount on June 30, 2017, September 30, 2017 and
December 31, 2017. All amounts of principal, interest and fees relating to Refinancing Loans not due and payable before the Term
B Loan Maturity Date are due and payable on the Term B Loan Maturity Date.”

 

		2.5	Amendments to Section 2.7.3: Repricing Event

 

Section 2.7.3 is hereby amended
and restated in its entirety as follows:

 

“If any Repricing Event occurs
on or prior to the date that is six months after the Second Amendment Effective Date, the Borrower agrees to pay to the Administrative
Agent, for the ratable account of each Term B Lender holding Term B Loans that are subject to such Repricing Event (including any
Term B Lender that is replaced pursuant to Section 2.14.2 (Replacement of Lenders) as a result of its refusal to consent to an
amendment giving rise to such Repricing Event), a fee in an amount equal to one percent (1.00%) of the aggregate principal amount
of the Term B Loans subject to such Repricing Event. Such fees shall be earned, due and payable upon the date of occurrence of
the respective Repricing Event.”

 

		2.6	Amendments to Section 2.8.2: Applicable Margin.

 

    

     

    

A.                
Section 2.8.2(a)(i) is hereby amended and restated in its entirety as follows:

 

(i)                
For Term B Loans prior to the Second Amendment Effective Date, three and one-quarter of one percent (3.25%) and on and after
the Second Amendment Effective Date, two and one-half percent (2.50%)

 

B.                
Section 2.8.2(b)(i) is hereby amended and restated in its entirety as follows:

 

(i)                
For Term B Loans prior to the Second Amendment Effective Date, four and one-quarter of one percent (4.25%) and on and after
the Second Amendment Effective Date, three and one-half percent (3.50%)

 

2.7       Amendments
to Schedule 2.1.4.

 

Schedule 2.1.4 is hereby
amended and restated in its entirety as set forth in Schedule 2.5 to this Amendment.

 

		2.8	Amendments to Section 11.5(o).

 

Section 11.5(o) is hereby amended
by substituting the reference therein to “Initial Term B Loans” to “Term B Loans”

 

2.9       Addition
of Section 11.19.

 

The Credit Agreement
is hereby amended by inserting a new Section 11.19 to read as follows:

 

“Section
11.19. Acknowledgement and Consent to Bail-In of EEA Financial Institutions. Notwithstanding anything to the contrary in
any Loan Document or in any other agreement, arrangement or understanding among any such parties, each party hereto acknowledges
that any liability of any EEA Financial Institution arising under any Loan Document, to the extent such liability is unsecured,
may be subject to the write-down and conversion powers of an EEA Resolution Authority and agrees and consents to, and acknowledges
and agrees to be bound by:

 

(a)       the
application of any Write-Down and Conversion Powers by an EEA Resolution Authority to any such liabilities arising hereunder which
may be payable to it by any party hereto that is an EEA Financial Institution; and

 

(b)       the
effects of any Bail-in Action on any such liability, including, if applicable;

 

(i) a reduction
in full or in part or cancellation of any such liability;

 

(ii) a conversion
of all, or a portion of, such liability into shares or other instruments of ownership in such EEA Financial Institution, its parent
undertaking, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or other instruments
of ownership will be accepted by it in lieu of any rights with respect to any such liability under this Agreement or any other
Loan Document; or

 

(iii) the
variation of the terms of such liability in connection with the exercise of the write-down and conversion powers of any EEA Resolution
Authority.”

 

		SECTION III.     	 CONDITIONS TO EFFECTIVENESS

 

    

     

    

This Amendment shall
become effective only upon, and the obligation of the New Term B Lenders shall be subject to, the satisfaction or waiver of all
of the following conditions precedent (the date of satisfaction or waiver of such conditions being referred to herein as the “Amendment
Effective Date”):

 

A.                
Borrowing Notice. The Administrative Agent shall have received a duly completed borrowing notice for the New
Term B Loans.

 

B.                
Execution. The Administrative Agent shall have received a counterpart signature page of this Amendment duly executed
by each Loan Party and a counterpart signature page of this Amendment and the Lender New Commitment, as applicable duly executed
by each New Term B Lender.

 

C.                
Opinion. The Administrative Agent shall have received a written opinion (addressed to the Administrative Agent
and the Lenders and dated the Amendment Effective Date) of Hodgson Russ LLP, counsel to the Borrower and the other Loan Parties
in form and substance reasonably satisfactory to the Administrative Agent. Each Loan Party hereby requests Hodgson Russ LLP to
deliver such opinion.

 

D.                
Fees. (i) Each of the Administrative Agent and Arranger shall have received all fees, premium (if any) and other
amounts accrued (whether or not otherwise due and payable on or prior to the Amendment Effective Date) including, reimbursement
or payment of all out-of-pocket expenses (including reasonable fees, charges and disbursements of counsel) required to be reimbursed
or paid by any Loan Party under any Loan Document, and including, without limitation, any amounts previously agreed in writing
by the Arranger (or any of its affiliates) and the Borrower and (ii) the entire aggregate principal amount of the Term B Loans
outstanding immediately prior to the Amendment Effective Date and all accrued interest, fees, premiums and other amounts (including
any amounts pursuant to Section 11.14) in connection therewith shall have been (or shall be deemed to have been) repaid in full
in a manner reasonably satisfactory to the Administrative Agent and all Interest Periods in respect of thereof shall have been
terminated.

 

E.                
Refinancing Term Notice. The Administrative Agent shall have received a Refinancing Term Notice in accordance
with Section 2.19.1 of the Credit Agreement.

 

F.                 
Secretary’s Certificate. The Administrative Agent shall have received such resolutions, certificates of
good standing, other certificates of Responsible Officers of the Borrower and Parent and such other documentation as the Administrative
Agent shall reasonably request.

 

G.               
Officer’s Certificate. The Administrative Agent shall have received a certificate of a financial officer
of the Borrower dated the Amendment Effective Date certifying that (A) the representations and warranties set forth in Section
IV of this Amendment shall be true and correct in all respects (or in all material respects if any such representation or warranty
is not by its terms already qualified as to materiality) as of the Amendment Effective Date as if made on and as of such date,
except to the extent that such representations and warranties specifically refer to an earlier date, in which case they shall be
true and correct in all respects (or in all material respects if any such representation or warranty is not by its terms already
qualified as to materiality) as of such earlier date and (B) no Default or Event of Default shall have occurred and be continuing.

 

Notwithstanding any other
provisions of this Amendment to the contrary, the Administrative Agent may appoint a fronting lender to act as the sole Additional
Term B Lender for purposes of facilitating funding on the Amendment Effective Date. Accordingly, any signature page hereto submitted
by or on behalf of an Additional Term B Lender other than such fronting lender will be deemed ineffective unless accepted by the
Administrative Agent in its sole discretion.

 

    

     

    

		SECTION IV.     	REPRESENTATIONS AND WARRANTIES

 

In order to induce
the Term B Lenders to enter into this Amendment and to amend the Credit Agreement in the manner provided herein, each of Parent
and the Borrower hereby represents and warrants to the Administrative Agent and each Term B Lender, as of the Amendment Effective
Date that, before and after giving effect to this Amendment, the following statements are true and correct in all material respects:

 

A.                
Power; Authorization. 

 

(i)                
Each Loan Party has the power and authority to execute, deliver and perform this Amendment and the Credit Agreement, as
amended by this Amendment (the “Amended Agreement”) and the other Loan Documents to which it is a party.
Each Loan Party has taken all necessary action to authorize the execution, delivery and performance of this Amendment, the Amended
Agreement and the other Loan Documents to which it is a party.

 

(ii)              
No consent or authorization of, or filing with, any Person (including, without limitation, any Governmental Authority) is
required in connection with the execution, delivery and performance by any Loan Party, or the validity or enforceability in accordance
with its terms against any Loan Party, of this Amendment, the Amended Agreement and the other Loan Documents to which it is a party
except for (i) such consents, authorizations and filings which have been obtained and are in full force and effect, (ii) such
consents, authorizations and filings which the failure to obtain or perform, individually or in the aggregate, could not reasonably
be expected to result in a Material Adverse Change, (iii) authorizations and filings required by applicable securities laws in
connection with the exercise of remedies with respect to pledged investment property and (iv) such filings as are necessary to
perfect the Liens of the Lenders created pursuant to the Loan Documents.

 

B.                
Enforceability. This Amendment has been duly executed and delivered by each of the Loan Parties and constitutes
the legal, valid and binding obligation of each Loan Party, and is enforceable against each Loan Party in accordance with its terms,
except as may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’
rights generally or by general principles of equity (regardless of whether enforcement is sought in a proceeding in equity or at
law).

 

C.                
Incorporation of Representations and Warranties from Credit Agreement. The representations and warranties contained
in Section 5 of the Amended Agreement are and will be true and correct in all material respects on and as of the Amendment Effective
Date to the same extent as though made on and as of that date, except to the extent such representations and warranties specifically
relate to an earlier date, in which case they were true and correct in all material respects on and as of such earlier date.

 

D.                
Absence of Default. No Default or Event of Default has occurred and is continuing or will result from this Amendment.

 

		SECTION V.     	REAFFIRMATION
OF GUARANTEES AND SECURITY INTERESTS

 

Each Loan Party hereby
acknowledges its receipt of a copy of this Amendment and its review of the terms and conditions hereof and hereby confirms and
consents to the terms and conditions of this Amendment and the transactions contemplated thereby, including the extension of New
Term B Loans. In addition, for the benefit of the Administrative Agent on behalf of the Secured Parties (including, without limitation,
the New Term B Lenders), each Loan Party hereby (a) affirms and confirms its guarantees, pledges, grants and other undertakings
under the Credit Agreement and the other Loan Documents to which it is a party, (b) agrees that (i) each Loan Document to which
it is a party shall continue to be in full force and effect and (ii) all guarantees, pledges, grants and other undertakings thereunder
shall continue to be in full force and effect and shall accrue to the benefit of the Secured Parties, including the New Term B
Lenders, and (c) acknowledges that from and after the date hereof, all New Term B Loans shall be deemed to be Obligations. Nothing
herein can or may be construed as a novation of the Credit Agreement or any other Loan Document.

 

    

     

    

		SECTION VI.     	  Ratification

 

This Amendment and
the Credit Agreement and each amendment, waiver or other modification to the Loan Documents set forth or contemplated herein and
therein shall be deemed to be effective pursuant to 2.19.1 of the Credit Agreement.

 

		SECTION VII.     	MISCELLANEOUS

 

A.                
Reference to and Effect on the Credit Agreement and the Other Loan Documents.

 

(i)                
On and after the Amendment Effective Date, each reference in the Credit Agreement to “this Agreement”, “hereunder”,
“hereof”, “herein” or words of like import referring to the Credit Agreement, and each reference in the
other Loan Documents to the “Credit Agreement”, “thereunder”, “thereof” or words of like import
referring to the Credit Agreement shall mean and be a reference to the Credit Agreement as amended by this Amendment.

 

(ii)              
Except as specifically amended by this Amendment, the Credit Agreement and the other Loan Documents shall remain in full
force and effect and are hereby ratified and confirmed.

 

(iii)            
This Amendment shall constitute a “Loan Document” for all purposes of the Credit Agreement and shall be administered
and construed pursuant to the terms of the Credit Agreement.

 

(iv)            
The execution, delivery and performance of this Amendment shall not constitute a waiver of any provision of, or operate
as a waiver of any right, power or remedy of any Agent or Lender under any Loan Document.

 

B.                
Limitation of Amendment and Waiver. Except as expressly set forth herein, the terms, provisions and conditions
of the Credit Agreement and the other Loan Documents shall remain in full force and effect and in all other respects are hereby
ratified and confirmed. Nothing herein shall be deemed to entitle the Borrower to a further consent to, or a further waiver, amendment,
modification or other change of, any of the terms, conditions, obligations, covenants or agreements contained in the Credit Agreement
or any other Loan Document in similar or different circumstances.

 

C.                
Headings. The descriptive headings of the several sections of this Amendment are inserted for convenience only
and shall not affect the meaning or construction of any of the provisions of this Amendment.

 

D.                
Applicable Law. THIS AMENDMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT
OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AMENDMENT AND THE TRANSACTIONS CONTEMPLATED HEREBY SHALL BE GOVERNED
BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK (EXCLUDING THE LAWS APPLICABLE TO CONFLICTS OR CHOICE OF
LAW).

 

    

     

    

E.                
Severability. Every provision of this Amendment is intended to be severable. If any term or provision
of this Amendment shall be invalid, illegal or unenforceable for any reason, the validity, legality and enforceability of the remaining
provisions shall not be affected or impaired thereby. Any invalidity, illegality or unenforceability of any term or provision of
this Amendment in any jurisdiction shall not affect the validity, legality or enforceability of any such term or provision in any
other jurisdiction.

 

F.                 
Counterparts. This Amendment may be executed in counterparts (and by different parties hereto in different counterparts),
each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of
an executed counterpart of a signature page of this Amendment by facsimile or in electronic (i.e., “pdf” or “tif”)
format shall be effective as delivery of a manually executed counterpart of this Amendment.

 

G.               
Status. Each party hereto acknowledges and agrees that the New Term B Loans constitute “Refinancing Term
B Indebtedness” under the Credit Agreement and the refinancing of the Term B Loans as contemplated hereby is permitted under
Section 2.19.1 of the Credit Agreement.

 

 

 

[Remainder of this page intentionally
left blank.]

 

    

     

    

IN WITNESS WHEREOF, each
of the undersigned has caused its duly authorized officer to execute and deliver this Amendment as of the date first written above.

 

 

	 	ADDITIONAL TERM B LENDER:
	 	 
	 	Credit
Suisse AG, Cayman Islands Branch, 

as a New Term B Lender (as an Additional Term B Lender and as a fronting New Term B Lender pursuant to the letter agreement between the Continuing Term B Lenders and Credit Suisse AG, Cayman Islands Branch dated March 17, 2017)

	 	 
	 	By: 	
        /s/ Christopher Day

	 	Name: 	Christopher Day
	 	Title: 	Authorized Signatory
	 	 	 
	 	 	 
	 	By: 	
        /s/ Joan Park

	 	Name:	 Joan Park
	 	Title: 	Authorized Signatory

 

	 	Notice Address:
	 	Credit Suisse AG, Cayman Islands Branch
	 	Eleven Madison Avenue, 23rd Floor
	 	New York, New York 10010
	 	Telephone: (212) 538-3525
	 	Facsimile: (212) 325-8315 
	 	Email: list.ops-collateral@credit-suisse.com

 

 

    

     

    

	 	INTEGER HOLDINGS CORPORATION,

as Parent

	 	 
	 	 
	 	By: 	
        /s/ Thomas J. Mazza

	 	Name: 	Thomas J. Mazza
	 	Title: 	Vice President

 

	 	GREATBATCH LTD.,

as the Borrower

	 	 
	 	 
	 	By:	
        /s/ Thomas J. Mazza

	 	Name: 	Thomas J. Mazza
	 	Title: 	Vice President

 

 

 

    

     

    

	 	CREDIT SUISSE SECURITIES (USA) LLC,

as Arranger

	 	 
	 	 
	 	By:	
        /s/ Colin Bathgate

	 	Name: 	Colin Bathgate
	 	Title: 	Managing Director

 

 

 

 

 

 

    

     

    

Consented to by:

 

MANUFACTURERS AND TRADERS TRUST COMPANY,

as Administrative Agent

 

	By:	/s/ Ryan Grimme	 
	 	Name: Ryan Grimme	 
	 	Title: Associate	 
	 	 	 
	 	 	 

 

 

 

 

 

    

     

    
	 	gbv,
llc, 

as a Loan Party
	 	 
	 	 
	 	By:	/s/ Timothy G. McEvoy
	 	Name: 	Timothy G. McEvoy
	 	Title: 	Senior Vice President

 

 

	 	Electrochem
solutions, inc, 

as a Loan Party
	 	 
	 	 
	 	By:	/s/ Thomas J. Mazza
	 	Name: 	 Thomas J. Mazza
	 	Title: 	 Vice President

 

 
	 	greatbatch-globe
tool, inc., 

as a Loan Party
	 	 
	 	 
	 	By:	/s/ Thomas J. Mazza
	 	Name: 	Thomas J. Mazza
	 	Title: 	Vice President

 

 
	 	lake
region medical holdings, inc., 

as a Loan Party
	 	 
	 	 
	 	By:	/s/ Thomas J. Mazza
	 	Name: 	Thomas J. Mazza
	 	Title: 	Vice President

 

 
	 	LAKE REGION MEDICAL, INC., 

as a Loan
Party
	 	 
	 	 
	 	By:	/s/ Thomas J. Mazza
	 	Name: 	Thomas J. Mazza
	 	Title: 	Vice President

 

    

     

    

	 	LAKE REGION MANUFACTURING, INC., 

as
a Loan Party
	 	 
	 	 
	 	By:	/s/ Thomas J. Mazza
	 	Name: 	Thomas J. Mazza
	 	Title: 	Vice President

 

 

	 	ACCELLENT LLC, 

as a Loan Party
	 	 
	 	 
	 	By:	/s/ Thomas J. Mazza
	 	Name: 	Thomas J. Mazza
	 	Title: 	Vice President

 

 

	 	AMERICAN TECHNICAL MOLDING, INC.,

 as
a Loan Party
	 	 
	 	 
	 	By:	/s/ Thomas J. Mazza
	 	Name: 	Thomas J. Mazza
	 	Title: 	Vice President

 

 

	 	G&D, LLC,

 as a Loan Party
	 	 
	 	 
	 	By:	/s/ Thomas J. Mazza
	 	Name: 	Thomas J. Mazza
	 	Title: 	Vice President

 

 

	 	UTI HOLDINGS, LLC,

 as a Loan Party
	 	 
	 	 
	 	By:	/s/ Thomas J. Mazza
	 	Name: 	Thomas J. Mazza
	 	Title: 	Vice President

 

    

     

    

	 	UTI HOLDING COMPANY, 

as a Loan Party
	 	 
	 	 
	 	By:	/s/ Thomas J. Mazza
	 	Name: 	Thomas J. Mazza
	 	Title: 	Vice President

 

 

	 	MEDSOURCE TECHNOLOGIES HOLDINGS,
LLC

 as a Loan Party
	 	 
	 	 
	 	By:	/s/ Thomas J. Mazza
	 	Name: 	Thomas J. Mazza
	 	Title: 	Vice President

 

 

	 	NOBLE-MET LLC,

 as a Loan Party
	 	 
	 	 
	 	By:	/s/ Thomas J. Mazza
	 	Name: 	Thomas J. Mazza
	 	Title: 	Vice President

 

 

	 	VENUSA, LTD.,

 as a Loan Party
	 	 
	 	 
	 	By:	/s/ Thomas J. Mazza
	 	Name: 	Thomas J. Mazza
	 	Title: 	Vice President

 

 

	 	SPECTRUM MANUFACTURING, INC.,

 as a
Loan Party
	 	 
	 	 
	 	By:	/s/ Thomas J. Mazza
	 	Name: 	Thomas J. Mazza
	 	Title: 	Vice President

 

    

     

    
	 	MEDSOURCE TECHNOLOGIES, LLC, 

as a
Loan Party
	 	 
	 	 
	 	By:	/s/ Thomas J. Mazza
	 	Name: 	Thomas J. Mazza
	 	Title: 	Vice President

 

 

	 	BRIMFIELD PRECISION, LLC,

 as a Loan
Party
	 	 
	 	 
	 	By:	/s/ Thomas J. Mazza
	 	Name: 	Thomas J. Mazza
	 	Title: 	Vice President

 

 

	 	KELCO ACQUISITION LLC,

 as a Loan
        Party
	 	 
	 	 
	 	By:	/s/ Thomas J. Mazza
	 	Name: 	Thomas J. Mazza
	 	Title: 	Vice President

 

 

	 	MEDSOURCE TECHNOLOGIES, NEWTON INC., 

as
a Loan Party
	 	 
	 	 
	 	By:	/s/ Thomas J. Mazza
	 	Name: 	Thomas J. Mazza
	 	Title: 	Vice President

 

 

	 	MEDSOURCE TRENTON LLC, 

as a Loan
        Party
	 	 
	 	 
	 	By:	/s/ Thomas J. Mazza
	 	Name: 	Thomas J. Mazza
	 	Title: 	Vice President

 

 

    

     

    
	 	PORTLYN, LLC, as a Loan Party
	 	 
	 	 
	 	By:	/s/ Thomas J. Mazza
	 	Name: 	Thomas J. Mazza
	 	Title: 	Vice President

 

 

 

 

 

 

    

     

    

[SCHEDULE 2.5 – TERM B LOAN COMMITMENTS]

 

Schedule 2.5 to Second
Amendment to Credit Agreement

 

 

 

	Lender	Term Loan B Commitment
	 	 
	CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH	$954,250,000
	TOTAL	$954,250,000

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}]]